These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 3005824

  • 1. Dopamine, acting through D-2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process.
    Cooper DM, Bier-Laning CM, Halford MK, Ahlijanian MK, Zahniser NR.
    Mol Pharmacol; 1986 Feb; 29(2):113-9. PubMed ID: 3005824
    [Abstract] [Full Text] [Related]

  • 2. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P, Olianas MC, Gessa GL.
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [Abstract] [Full Text] [Related]

  • 3. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
    Roseboom PH, Gnegy ME.
    Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
    [Abstract] [Full Text] [Related]

  • 4. Evidence that the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland is associated with an inhibitory guanyl nucleotide component.
    Cote TE, Frey EA, Grewe CW, Kebabian JW.
    J Neural Transm Suppl; 1983 Jan; 18():139-47. PubMed ID: 6308147
    [Abstract] [Full Text] [Related]

  • 5. Forskolin potentiates the stimulation of rat striatal adenylate cyclase mediated by D-1 dopamine receptors, guanine nucleotides, and sodium fluoride.
    Battaglia G, Norman AB, Hess EJ, Creese I.
    J Neurochem; 1986 Apr; 46(4):1180-5. PubMed ID: 3005508
    [Abstract] [Full Text] [Related]

  • 6. Characterization of D-2 dopamine receptors in a tumor of the rat anterior pituitary gland.
    Lin C, McGonigle P, Molinoff PB.
    J Pharmacol Exp Ther; 1987 Sep; 242(3):950-6. PubMed ID: 2958621
    [Abstract] [Full Text] [Related]

  • 7. D-2 dopamine receptor-mediated inhibition of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland requires guanosine 5'-triphosphate.
    Cote TE, Grewe CW, Tsuruta K, Stoof JC, Eskay RL, Kebabian JW.
    Endocrinology; 1982 Mar; 110(3):812-9. PubMed ID: 7056233
    [Abstract] [Full Text] [Related]

  • 8. Antagonism of l-stepholidine on D2 receptor-mediated inhibition of synaptosomal adenylate cyclase in rat corpus striatum.
    Hu G, Hu Y, Jin GZ.
    Zhongguo Yao Li Xue Bao; 1992 Mar; 13(2):104-10. PubMed ID: 1598823
    [Abstract] [Full Text] [Related]

  • 9. M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.
    Schoffelmeer AN, Hogenboom F, Mulder AH.
    J Pharmacol Exp Ther; 1988 May; 245(2):658-63. PubMed ID: 2452877
    [Abstract] [Full Text] [Related]

  • 10. D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture.
    Weiss S, Sebben M, Garcia-Sainz JA, Bockaert J.
    Mol Pharmacol; 1985 Jun; 27(6):595-9. PubMed ID: 2987658
    [Abstract] [Full Text] [Related]

  • 11. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
    Olianas MC, Maullu C, Onali P.
    Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
    [Abstract] [Full Text] [Related]

  • 12. Desensitization of rat striatal dopamine-stimulated adenylate cyclase after acute amphetamine administration.
    Barnett JV, Kuczenski R.
    J Pharmacol Exp Ther; 1986 Jun; 237(3):820-5. PubMed ID: 2940359
    [Abstract] [Full Text] [Related]

  • 13. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ, Albers LJ, Le H, Creese I.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [Abstract] [Full Text] [Related]

  • 14. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
    Hess EJ, Battaglia G, Norman AB, Creese I.
    Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940
    [Abstract] [Full Text] [Related]

  • 15. Chronic sulpiride treatment produces supersensitivity of striatal adenylate cyclase to dopamine in sexually immature or adult castrated rats.
    Gnegy ME, Bernabei A, Treisman G.
    J Pharmacol Exp Ther; 1983 Mar; 224(3):627-33. PubMed ID: 6827485
    [Abstract] [Full Text] [Related]

  • 16. Comparison of inhibitory actions of chlorpromazine or its 7,8-dihydroxy and 7,8-dioxo-didesmethyl analogs on DA-sensitive adenylate cyclase and calmodulin activation of phosphodiesterase in rat striatum.
    Palmer GC, Pajer KA, Manian AA.
    Arch Int Pharmacodyn Ther; 1985 Feb; 273(2):202-11. PubMed ID: 2988471
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological characterization of rat retinal dopamine receptors.
    Qu ZX, Fertel R, Neff NH, Hadjiconstantinou M.
    J Pharmacol Exp Ther; 1989 Feb; 248(2):621-5. PubMed ID: 2493095
    [Abstract] [Full Text] [Related]

  • 18. D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo.
    Saller CF, Salama AI.
    J Pharmacol Exp Ther; 1986 Mar; 236(3):714-20. PubMed ID: 3005552
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
    Enjalbert A, Bockaert J.
    Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
    [Abstract] [Full Text] [Related]

  • 20. Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.
    Lau YS, Runice C, Dowd F.
    J Pharmacol Exp Ther; 1984 Apr; 229(1):32-7. PubMed ID: 6323689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.